« Go Back

Pipeline Therapeutics Announces Participation in Upcoming Investor Conferences

SAN DIEGO–(BUSINESS WIRE)–Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that management will participate in the following investor conferences during October 2022:

  • Cantor Fitzgerald Neurology & Psychiatry Conference, October 6, in San Francisco, CA
  • BMO Life Sciences Private Company Showcase October 13, in New York, NY
  • Oppenheimer’s Private Company Showcase, October 17-18, in Palo Alto, CA
  • 2nd Annual Needham Biotech Private Company Virtual 1×1 Forum, October 18-19
  • Bank of America Private Company Showcase, October 20, in Boston, MA

About Pipeline Therapeutics
Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair. The Company has a broad pipeline of programs to address multiple CNS disorders. Its flagship program, PIPE-307, has completed two Phase 1 clinical trials – a SAD/MAD study and a PET study – in healthy volunteers, and has received Investigational New Drug clearance from the Food and Drug Administration to initiate clinical development in relapsing-remitting MS patients.

For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.

Contacts

Company Contact:
Peter Slover
CFO
ir@pipeline-tx.com

Investor Contact:
Amy Conrad
858-914-1962
amy@juniper-point.com

« Go Back

Pipeline Therapeutics to Participate in the UBS Virtual Biotechnology Private Company Symposium

SAN DIEGO, September 8, 2022 – Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that company management will participate virtually in the UBS Biotechnology Private Company Symposium, being held September 21-22, 2022.  Pipeline will present a company overview and will conduct virtual one-on-one meetings with investors during the conference.

About Pipeline Therapeutics
Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair.  The Company has a broad pipeline of programs to address multiple CNS disorders. Its flagship program, PIPE-307, has completed two Phase 1 clinical trials – a SAD/MAD study and a PET study – in healthy volunteers, and has received Investigational New Drug clearance from the Food and Drug Administration to initiate clinical development in relapsing-remitting MS patients.  

For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.

Company Contact:
Peter Slover
CFO
ir@pipeline-tx.com

Investor Contact:
Amy Conrad
858-914-1962
amy@juniper-point.com

« Go Back

Jules Lee

Director, Clinical Operations